Loading…
Moor Herbs, Inc. was cited for manufacturing and marketing unapproved new drugs and misbranded drugs, including products with therapeutic claims such as "Full Body Antibiotic," "Anti-Viral," "Blood Pressure Normalizer," and "Tumor Release" that lacked FDA approval. An FDA inspection of the company's Detroit-area facility from February to March 2023, combined with a review of their website (moorherbs.com), revealed serious violations of the Federal Food, Drug, and Cosmetic Act and FDA regulations. The company was taking orders for these products online despite lacking the required new drug applications or proper substantiation for their therapeutic claims.